AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
SYMBICORT® in the Treatment of COPD
Completed
- Conditions
- COPD
- First Posted Date
- 2007-11-28
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00564499
Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer
Completed
- Conditions
- Advanced Breast Cancer
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00562458
Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11
- Registration Number
- NCT00562250
- Locations
- 🇦🇷
Local Institution, Vicente Lopez, Buenos Aires, Argentina
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
Phase 2
Completed
- Conditions
- Breast CancerProstate CancerBone Neoplasms
- Interventions
- Drug: AZD0530Drug: Zoledronic Acid
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 139
- Registration Number
- NCT00558272
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Electronic Study for Anastrozole Pharmacovigilance Evaluation
Completed
- Conditions
- Early Breast Cancer
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2008-07-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1850
- Registration Number
- NCT00558168
Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia
Completed
- Conditions
- Patients With Dyslipidemia
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2011-04-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00557778
- Locations
- 🇧🇷
Research Site, Campinas, Sao Paulo, Brazil
NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT00557297
- Locations
- 🇱🇻
Research Site, Ventspils, Latvia
A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 37
- Registration Number
- NCT00556023
- Locations
- 🇮🇹
Research Site, Roma, Italy
Patient's Anastrozole Compliance to Therapy Programme
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2011-12-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4923
- Registration Number
- NCT00555867
Renal Impairment in Type 2 Diabetic Subjects
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00554450
- Locations
- 🇺🇸
Prism Research, St. Paul, Minnesota, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸Elite Research Institute, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath